The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)pandemic has been a major health burden in the world.So far,many strategies have been investigated to control the spread of COVID-19,including social dist...The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)pandemic has been a major health burden in the world.So far,many strategies have been investigated to control the spread of COVID-19,including social distancing,disinfection protocols,vaccines,and antiviral treatments.Despite the significant achievement,due to the constantly emerging new variants,COVID-19 is still a great challenge to the global healthcare system.It is an urgent demand for the development of new therapeutics and technologies for containing the wild spread of SARS-CoV-2.Inhaled administration is useful for the treatment of lung and respiratory diseases,and enables the drugs to reach the site of action directly with benefits of decreased dose,improved safety,and enhanced patient compliance.Nanotechnology has been extensively applied in the prevention and treatment of COVID-19.In this review,the inhaled nanomedicines and antibodies,as well as intranasal nanodrugs,for the prevention and treatment of COVID-19 are summarized.展开更多
To the Editor:As of January 27,2022,there were 363,062,293 cases and 5,645,884deaths from the COVID-19 pandemic1.The prevalent mutated strains have aggravated the global pandemic2.SARS-Co V-2 is highly mutable,and the...To the Editor:As of January 27,2022,there were 363,062,293 cases and 5,645,884deaths from the COVID-19 pandemic1.The prevalent mutated strains have aggravated the global pandemic2.SARS-Co V-2 is highly mutable,and the mutations on the spike(S)protein resulted in a high transmission of COVID-19 and vaccine breakthrough infection3.For example,there is a notable decrease in neutralizing ability of BNT162b2 vaccination-elicited antibodies against the Delta and other variants4,5,and attenuation of peak viral burden and vaccine effectiveness are reduced with Delta variant6.展开更多
基金support of the National Key Research and Development Program of China 627(2021YFE0103100,China)National Nature Science Foundation of China(81925035)+4 种基金Shanghai Sci-Tech Innovation Initiative(19431903100 and 18430740800,China)the Sanofi-SIBS Yong Faculty Award(China)the Youth Innovation Promotion Association(China)granted as High-level New R&D Institute(2019B090904008)High-level Innovative Research Institute(2021B0909050003)by Department of Science and Technology of Guangdong Province,China。
文摘The severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)pandemic has been a major health burden in the world.So far,many strategies have been investigated to control the spread of COVID-19,including social distancing,disinfection protocols,vaccines,and antiviral treatments.Despite the significant achievement,due to the constantly emerging new variants,COVID-19 is still a great challenge to the global healthcare system.It is an urgent demand for the development of new therapeutics and technologies for containing the wild spread of SARS-CoV-2.Inhaled administration is useful for the treatment of lung and respiratory diseases,and enables the drugs to reach the site of action directly with benefits of decreased dose,improved safety,and enhanced patient compliance.Nanotechnology has been extensively applied in the prevention and treatment of COVID-19.In this review,the inhaled nanomedicines and antibodies,as well as intranasal nanodrugs,for the prevention and treatment of COVID-19 are summarized.
基金the support of the National Key Research and Development Program of China(2021YFE0103100,China)National Natural Science Foundation of China of China(81925035 and 81521005)+2 种基金Shanghai Sci-Tech Innovation Initiative(19431903100,18430740800,China)the Sanofi-SIBS Yong Faculty Award(China)the Youth Innovation Promotion Association(China)。
文摘To the Editor:As of January 27,2022,there were 363,062,293 cases and 5,645,884deaths from the COVID-19 pandemic1.The prevalent mutated strains have aggravated the global pandemic2.SARS-Co V-2 is highly mutable,and the mutations on the spike(S)protein resulted in a high transmission of COVID-19 and vaccine breakthrough infection3.For example,there is a notable decrease in neutralizing ability of BNT162b2 vaccination-elicited antibodies against the Delta and other variants4,5,and attenuation of peak viral burden and vaccine effectiveness are reduced with Delta variant6.
